The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma
Abstract
Purpose: Temozolomide (Temodar; Schering-Plough Corp, Kenilworth, NJ) is an imidazole tetrazinone that undergoes chemical conversion to the active methylating agent 5-(3-methyltriazen-1yl)imidazole-4-carboximide under physiologic conditions. Previous studies have confirmed activity of Temodar in the treatment of progressive and newly diagnosed malignant gliomas. We have extended these results, and now we report results of a phase II trial of Temodar for patients with progressive, low-grade glioma. Patients and Methods: Temodar was administered orally once a day for five consecutive days (in a fasting state) at a starting dose of 200 mg/m 2/d. Treatment cycles were repeated every 28 days following the first daily dose of Temodar. Response criteria used a combination of magnetic resonance imaging and physical examination to evaluate activity. Results: Forty-six patients with low-grade glioma have been treated to date. The objective response rate was 61% (24% complete response and 37% partial response), with an additional 35% of patients having stable disease. Median progression-free survival (PFS) was 22 months (95% confidence interval [CI], 15 to ∞ months) with a 6-month PFS of 98% (95% CI, 94% to 100%) and a 12-month PFS of 76% (95% CI, 63% to 92%). Toxicity observed during the study was limited to only six patients. Three patients experienced grade 3 neutropenia, with a duration greater than 3 weeks in one patient, and two patients experienced grade 3 thrombocytopenia. One patient experienced ≥ grade 4 toxicity, with intracerebral hemorrhage, neutropenia, thrombocytopenia, sepsis, and death. Conclusion:Initial results indicate that Temodar may be active in the treatment of low-grade glioma, and thus, further evaluation of this agent in the treatment of these tumors is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929
Self-citationYung, W. K. A., Prados, M. D., Yaya-Tur, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R., Olson, J., Chang, S. M., O'Neill, A. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2762 · Cited by 761
Self-citationKarim, A. B. M. F., Maat, B., Hatlevoll, R., Menten, J., Rutten, E. H. J. M., Thomas, D. G. T., Mascarenhas, F., Horiot, J. C., Parvinen, L. M., van Reijn, M., et al. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00352-5 · Cited by 694
Packer, R. J., Ater, J., Allen, J., Phillips, P., Geyer, R., Nicholson, H. S., Jakacki, R., Kurczynski, E., Needle, M., Finlay, J., et al. (1997) · Journal of Neurosurgery · doi:10.3171/jns.1997.86.5.0747 · Cited by 636
Self-citationNeurosurgical management of low-grade astrocytoma of the cerebral hemispheres
Laws, E. R., Taylor, W. F., Clifton, M. B., & Okazaki, H. (1984) · Journal of Neurosurgery · doi:10.3171/jns.1984.61.4.0665 · Cited by 512
Davis, F. G., Freels, S., Grutsch, J., Barlas, S., & Brem, S. (1998) · Journal of Neurosurgery · doi:10.3171/jns.1998.88.1.0001 · Cited by 482
Cairncross, G., Macdonald, D., Ludwin, S., Lee, D., Cascino, T., Buckner, J., Fulton, D., Dropcho, E., Stewart, D., & Schold, C. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2013 · Cited by 442
Friedman, H. S., McLendon, R. E., Kerby, T., Dugan, M., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3851 · Cited by 423
Self-citationLeighton, C., Fisher, B., Bauman, G., Depiero, S., Stitt, L., MacDonald, D., & Cairncross, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1294 · Cited by 365
Successful chemotherapy for recurrent malignant oligodendroglioma
Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 344
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
Houillier, C., Wang, X., Kaloshi, G., Mokhtari, K., Guillevin, R., Laffaire, J., Paris, S., Boisselier, B., Idbaih, A., Laigle-Donadey, F., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f96282 · Cited by 535
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
Soffietti, R., Baumert, B. G., Bello, L., Von Deimling, A., Duffau, H., Frénay, M., Grisold, W., Grant, R., Graus, F., Hoang‐Xuan, K., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03151.x · Cited by 505
Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Kantor, G., Taphoorn, M. J. B., Hassel, M. B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30313-8 · Cited by 495
Survival and low-grade glioma: the emergence of genetic information
Claus, E. B., Walsh, K. M., Wiencke, J. K., Molinaro, A. M., Wiemels, J. L., Schildkraut, J. M., Bondy, M. L., Berger, M., Jenkins, R., & Wrensch, M. (2015) · Neurosurgical Focus · doi:10.3171/2014.10.focus12367 · Cited by 445
Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma
Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., Cairncross, J. G., & on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-165 · Cited by 373
Hoang-Xuan, K., Capelle, L., Kujas, M., Taillibert, S., Duffau, H., Lejeune, J., Polivka, M., Crinière, E., Marie, Y., Mokhtari, K., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.169 · Cited by 356
Shaw, E. G., Wang, M., Coons, S. W., Brachman, D. G., Buckner, J. C., Stelzer, K. J., Barger, G. R., Brown, P. D., Gilbert, M. R., & Mehta, M. P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.8598 · Cited by 355
Buckner, J. C., Brown, P. D., O'Neill, B. P., Meyer, F. B., Wetmore, C. J., & Uhm, J. H. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.10.1271 · Cited by 341
Low-grade gliomas in adults: A review
Sanai, N., Chang, S., & Berger, M. S. (2011) · Journal of Neurosurgery · doi:10.3171/2011.7.jns101238 · Cited by 291
Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome
Kaloshi, G., Benouaich-Amiel, A., Diakite, F., Taillibert, S., Lejeune, J., Laigle-Donadey, F., Renard, M.-A., Iraqi, W., Idbaih, A., Paris, S., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000262034.26310.a2 · Cited by 286
Duffau, H., & Taillandier, L. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou153 · Cited by 281
Pace, A., Vidiri, A., Galiè, E., Carosi, M., Telera, S., Cianciulli, A. M., Canalini, P., Giannarelli, D., Jandolo, B., & Carapella, C. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg502 · Cited by 263
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas
Brada, M., Viviers, L., Abson, C., Hines, F., Britton, J., Ashley, S., Sardell, S., Traish, D., Gonsalves, A., Wilkins, P., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg371 · Cited by 261
Forst, D. A., Nahed, B. V., Loeffler, J. S., & Batchelor, T. T. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0345 · Cited by 253
Fisher, B. J., Hu, C., Macdonald, D. R., Lesser, G. J., Coons, S. W., Brachman, D. G., Ryu, S., Werner-Wasik, M., Bahary, J.-P., Liu, J., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.11.012 · Cited by 163
Schaff, L. R., & Lassman, A. B. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.02.008 · Cited by 13
Metadata
- Authors
- Quinn, J. A., Reardon, D. A., Friedman, A. H., Rich, J. N., Sampson, J. H., Provenzale, J. M., McLendon, R. E., Gururangan, S., Bigner, D. D., Herndon, J. E., Avgeropoulos, N., Finlay, J., Tourt-Uhlig, S., Affronti, M. L., Evans, B., Stafford-Fox, V., Zaknoen, S., & Friedman, H. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-02-15
- Volume
- 21
- Issue
- 4
- Pages
- 646-651
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106649727
- Cited by
- 258
- References
- 24
- FWCI
- 11.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.